Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
SkinJect, Inc.
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alpha Tau Medical LTD.
University of Rochester
University of Pittsburgh
Centre Hospitalier Universitaire Vaudois
CivaTech Oncology
University of California, Irvine
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Hospital Augsburg
Case Comprehensive Cancer Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Philogen S.p.A.
McGuire Institute
Philogen S.p.A.
Jules Bordet Institute
Replimune Inc.
Ohio State University Comprehensive Cancer Center
University of California, San Diego
Roswell Park Cancer Institute
Helsinki University Central Hospital
US Dermatology Partners, Phoenix
Highlight Therapeutics
VA Office of Research and Development
Regeneron Pharmaceuticals
University of Southern California
Mashhad University of Medical Sciences
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Melanoma Institute Australia
Alpha Tau Medical LTD.
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Institut de Cancérologie de Lorraine
Case Comprehensive Cancer Center
Institut Curie
Centre Hospitalier Universitaire de Nīmes
Incyte Corporation
National Cancer Institute (NCI)
Bispebjerg Hospital
University Hospital, Lille
Jemincare
Bruce Robinson, MD
NYU Langone Health